Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response

Haematologica. 2015 Aug;100(8):e299-301. doi: 10.3324/haematol.2015.124685. Epub 2015 Mar 27.
No abstract available

Keywords: discordant response; imatinib-treated CML.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Chromosome Aberrations
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Imatinib Mesylate / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Protein Kinase Inhibitors / therapeutic use*
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl